MeVis: MeVis Medical Solutions Reports First Half 2023 Earnings

MeVis Medical Solutions ( ETR:M3V ) First Half 2023 Results Key Financial Results Revenue: €9.10m (up 6.5% from 1H 2022). Net income: €1.83m (down 47% from 1H 2022). Profit margin: 20% (down from 40% in 1H 2022). The decrease in margin was driven by higher expenses. earnings-and-revenue-history All figures shown in the chart above are for the trailing 12 month (TTM) period MeVis Medical Solutions shares are down 1.9% from a week ago. Risk Analysis What about risks? Every company has them, and we've spotted 2 warning signs for MeVis Medical Solutions (of which 1 can't be ignored!) you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Join A Paid User Research Session You'll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here